KIT and cancer: Therefore, cancer‐related RTK become preferable targets for ADC development, e.g. RON, PTK7, FLT3, FGFR2, FGFR3, ERBB3, KIT and EPHA2 (Fauvel and Yasri, 2014; Katoh, 2017).